Development of a limited-sampling model for prediction of doxorubicin exposure in dogs

Authors

  • L. A. Wittenburg,

    Corresponding author
    1. Department of Clinical Sciences, Colorado State University Animal Cancer Center, Fort Collins, CO, USA
    • Correspondence address:

      L. A. Wittenburg

      Department of Clinical Sciences

      Colorado State University Animal Cancer Center

      300 W. Drake Rd., Fort Collins, CO, USA

      e-mail: lwittenb@colostate.edu

    Search for more papers by this author
  • D. H. Thamm,

    1. Department of Clinical Sciences, Colorado State University Animal Cancer Center, Fort Collins, CO, USA
    2. University of Colorado Comprehensive Cancer Center, Anschutz Medical Campus, Aurora, CO, USA
    Search for more papers by this author
  • D. L. Gustafson

    1. Department of Clinical Sciences, Colorado State University Animal Cancer Center, Fort Collins, CO, USA
    2. University of Colorado Comprehensive Cancer Center, Anschutz Medical Campus, Aurora, CO, USA
    Search for more papers by this author

Abstract

Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.

Ancillary